Inici › Càncer de bufeta › Massachusetts › Boston
Assaigs clínics de Càncer de bufeta a Boston, MA
26 estudis de Càncer de bufeta busquen participants en centres de Boston i voltants (en un radi d'uns 30 milles). Obre un estudi per veure qui hi pot participar i com contactar amb l'equip.
Text oficial de l'estudi (anglès)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
ReclutantFase 1
- Massachusetts General Hospital, Boston
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
ReclutantFase 3
- Brigham and Women's Hospital, Boston
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
ReclutantFase 2
- Massachusetts General Hospital Cancer Center, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
ReclutantFase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
ReclutantFase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
ReclutantFase 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Patient-Centered Surgical Prehabilitation
ReclutantVoluntaris sans benvinguts
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
ReclutantFase 3
- Dana Farber Cancer Institute ( Site 0783), Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
ReclutantFase 3
- Massachusetts General Hospital, Boston
Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy
Reclutant
- Dana Farber Cancer Institute, Boston
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
ReclutantFase 1
- Dana-Farber Cancer Institute, Boston
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
ReclutantFase 2
- Brigham and Women's Hospital, Boston
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
ReclutantFase 2
- Brigham and Women's Hospital, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
ReclutantFase 1
- Massachusetts General Hospital, Boston
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
ReclutantFase 3
- Massachusetts General Hospital Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutantFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
ReclutantFase 1/2
- Brigham and Women's Hospital, Boston
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
ReclutantFase 2/3
- Local Institution - 0195, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
ReclutantFase 2
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
ReclutantFase 3
- Research Site, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
ReclutantFase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- i 2 més
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
ReclutantEstudi observacional
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
Reclutant
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Sacituzumab Govitecan Plus EV in Metastatic UC
ReclutantFase 1/2
- Dana Farber Cancer Institute, Boston
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
Reclutant
- Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
ReclutantFase 3
- Brigham and Women's Hospital, Boston
Assaigs de Càncer de bufeta en altres ciutats
- New York City, NY35 estudis
- Nashville, TN31 estudis
- Houston, TX31 estudis
- Dallas, TX27 estudis
- Washington, DC26 estudis
- Los Angeles, CA24 estudis
- Baltimore, MD24 estudis
- St. Louis, MO22 estudis
- Philadelphia, PA21 estudis
- Seattle, WA21 estudis
- Edison, NJ21 estudis
- Chicago, IL21 estudis
Altres estudis a Boston
- Càncer de mama111 estudis
- Càncer de pulmó de cèl·lules no petites90 estudis
- Càncer (tots els tipus)86 estudis
- Càncer colorrectal63 estudis
- Càncer metastàtic63 estudis
- Càncer de pulmó62 estudis
- Càncer d'ovari61 estudis
- Càncer de pròstata59 estudis
- Depressió52 estudis
- Càncer d'endometri50 estudis
- Insuficiència cardíaca44 estudis
- Leucèmia mieloide aguda44 estudis
De ClinicalTrials.gov, dades recuperades el 5 d’oct. 2026. Cada estudi estableix els seus propis criteris d'elegibilitat; l'equip de l'estudi decideix qui hi pot participar.